Evidence map›Paper›PMID 32821824›Full record

ArticleScience advances2020

Development of a potent Zika virus vaccine using self-amplifying messenger RNA.

Kate Luisi, Kaitlyn M Morabito, Katherine E Burgomaster, Mayuri Sharma, Wing-Pui Kong, Bryant M Foreman, Sonal Patel, Brian Fisher, Maya A Aleshnick, Jason Laliberte and 21 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
9.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 80 citations in OpenAlex.

  1. Article
  2. Review
  3. Bioprofiling and vaccine development for Zika virus.Science China. Life sciences · 2025
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Research progress of mosquito-borne virus mRNA vaccines.Molecular therapy. Methods & clinical development · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 2 institutions in 1 country.

Kate LuisiGSK Vaccines, Rockville, MD 20850, USA.ORCID 0000-0003-2945-8712
Kaitlyn M MorabitoVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-4849-4690
Katherine E BurgomasterLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-5524-2467
Mayuri SharmaGSK Vaccines, Rockville, MD 20850, USA.
Wing-Pui KongVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Bryant M ForemanLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Sonal PatelGSK Vaccines, Rockville, MD 20850, USA.
Brian FisherVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Maya A AleshnickLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-5471-4242
Jason LaliberteGSK Vaccines, Rockville, MD 20850, USA.
Madison WallaceGSK Vaccines, Rockville, MD 20850, USA.ORCID 0000-0003-3569-1764
Tracy J RuckwardtVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-0007-7169
David N GordonLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Christine LintonGSK Vaccines, Rockville, MD 20850, USA.
Nicole RuggieroGSK Vaccines, Rockville, MD 20850, USA.
Jessica L CohenGSK Vaccines, Rockville, MD 20850, USA.
Russell JohnsonGSK Vaccines, Rockville, MD 20850, USA.
Kunal AggarwalGSK Vaccines, Rockville, MD 20850, USA.
Sung-Youl KoVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-5004-6336
Eun Sung YangVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Rebecca S PelcLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-5080-4945
Kimberly A DowdLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-3641-6852
Derek O'HaganGSK Vaccines, Rockville, MD 20850, USA.
Jeffrey UlmerGSK Vaccines, Rockville, MD 20850, USA.
Sally MossmanGSK Vaccines, Rockville, MD 20850, USA.
Anna SamborGSK Vaccines, Rockville, MD 20850, USA.
Edith LepineGSK Vaccines, Rockville, MD 20850, USA.
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-5293-4695
Theodore C PiersonLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-3795-4348
Barney S GrahamVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-8112-0853
Dong YuGSK Vaccines, Rockville, MD 20850, USA.ORCID 0000-0002-3412-6440
GlaxoSmithKline (United States) · USNational Institutes of Health · US

Funding

Vaccine Research and Development for Endemic, Emerging, and Resurgent VirusesZIAAI005128 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KANEKIYO, MASARU · 2016 to 2025
$50.8M
The humoral response to Zika virus infection and vaccinationZIAAI001209 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI PIERSON, THEODORE · 2016 to 2025
$22.0M
6 · The paper itself

Abstract

Zika virus (ZIKV) is the cause of a pandemic associated with microcephaly in newborns and Guillain-Barre syndrome in adults. Currently, there are no available treatments or vaccines for ZIKV, and the development of a safe and effective vaccine is a high priority for many global health organizations. We describe the development of ZIKV vaccine candidates using the self-amplifying messenger RNA (SAM) platform technology delivered by cationic nanoemulsion (CNE) that allows bedside mixing and is particularly useful for rapid responses to pandemic outbreaks. Two immunizations of either of the two lead SAM (CNE) vaccine candidates elicited potent neutralizing antibody responses to ZIKV in mice and nonhuman primates. Both SAM (CNE) vaccines protected these animals from ZIKV challenge, with one candidate providing complete protection against ZIKV infection in nonhuman primates. The data provide a preclinical proof of concept that a SAM (CNE) vaccine candidate can rapidly elicit protective immunity against ZIKV.

Indexed as

Viral VaccinesZika VirusZika Virus InfectionAnimalsAntibodies, ViralMiceRNA, MessengerAntibodies, ViralRNA, MessengerViral Vaccines

Identifiers

PMID32821824
PMCPMC7413734
OpenAlexW3048018410

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.